Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics by unknown
RESEARCH Open Access
Identifying EGFR mutation-induced drug
resistance based on alpha shape model
analysis of the dynamics
Lichun Ma*, Bin Zou and Hong Yan
Abstract
Background: Epidermal growth factor receptor (EGFR) mutation-induced drug resistance is a difficult problem in
lung cancer treatment. Studying the molecular mechanisms of drug resistance can help to develop corresponding
treatment strategies and benefit new drug design.
Methods: In this study, Rosetta was employed to model the EGFR mutant structures. Then Amber was carried out
to conduct molecular dynamics (MD) simulation. Afterwards, we used Computational Geometry Algorithms Library
(CGAL) to compute the alpha shape model of the mutants.
Results: We analyzed the EGFR mutation-induced drug resistance based on the motion trajectories obtained from
MD simulation. We computed alpha shape model of all the trajectory frames for each mutation type. Solid angle
was used to characterize the curvature of the atoms at the drug binding site. We measured the knob level of the
drug binding pocket of each mutant from two ways and analyzed its relationship with the drug response level.
Results show that 90 % of the mutants can be grouped correctly by setting a certain knob level threshold.
Conclusions: There is a strong correlation between the geometric properties of the drug binding pocket of the
EGFR mutants and the corresponding drug responses, which can be used to predict the response of a new EGFR
mutant to a drug molecule.
Keywords: Epidermal growth factor receptor (EGFR), Non-small-cell lung cancer (NSCLC), Gefitinib, Drug binding
site, Molecular dynamics, Alpha shape modeling, Solid angle
Background
Lung cancer is the leading cause of cancer deaths world-
wide [1–3]. Non-small-cell lung carcinoma (NSCLC) is
the most common lung cancer type, accounting for over
80 % of all the lung cancer cases [4, 5]. Epidermal
growth factor receptor (EGFR) is found to overexpress
in about 60 % of NSCLC patients, making it a target of
many treatment strategies [6–8]. EGFR, also called
HER1 or ErbB-1, is a member of the ErbB family, which
also contains HER2 (ErbB-2), HER3 (ErbB-3) and HER4
(ErbB-4) [9, 10]. It is a functional protein that can be ac-
tivated through binding with cognate ligands, such as
epidermal growth factor [11]. On ligand binding, EGFR
can form a homodimer (EGFR-EGFR) or heterodimers
(dimerization with other family members), leading to the
phosphorylation of specific residues at the intracellular
tyrosine kinase (TK) domain. These phosphorylated
residues act as docking sites for downstream proteins,
triggering the downstream pathways that modulate cel-
lular proliferation and survival [12, 13]. However, aber-
rant EGFR signaling, sometimes caused by mutations at
the EGFR TK domain, can lead to tumor growth and
progression in the lung [14–16]. Gefitinib is a commonly
used drug to target the EGFR TK domain to block the ac-
tivation of EGFR and its downstream signaling [17–22].
Nevertheless, after a period of treatment, drug resistance
occurs usually due to a second mutation (e.g. T790M)
or the activating of other receptor tyrosine kinases (e.g.
c-Met) [23–26].
A lot of research has focused on drug resistance mech-
anisms in lung cancer [27–30]. Computational methods
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are successfully applied in these studies, benefiting from
their advantages of low cost, easy implementation and
capacity of processing large datasets [31–33]. Zhu et al.
employed support vector machine based classifiers to
correlate the collected features (clinicopathologic features
and immunomarkers) and the overall survival of NSCLC
patients [34]. Wang et al. used the personal features of
168 NSCLC patients coupled with EGFR mutant-drug
binding free energy features to build a classification model
to predict the drug response levels, and obtained a best
testing accuracy of 95.83 % [35].
To decode the EGFR mutation-induced drug resistance,
it is very important to analyze the interaction between the
EGFR mutants and a drug molecule. The geometric prop-
erties of the drug binding pocket can affect the binding af-
finity of two molecules. Intuitively, a concave shape may
have a higher binding affinity with a drug molecule than a
convex shape because of structural complementary char-
acteristics. In addition, a shape with a low convex degree
could bind more tightly on a drug molecule relative to a
shape with high convex degree. Therefore, different from
other studies which focused on personal features, energy
features as well as immunomarkers, we use the geometric
properties of the drug binding pocket of the EGFR mu-
tants to identify the drug resistance mechanisms. Com-
pared with the EGFR-drug binding free energy used by
Wang et al. [35], which shows the overall binding affinity,
the geometric features can provide specific structural in-
formation of each atom at the drug binding pocket. These
structural information offers clues on how to modify the
drug structure and the spatial relations of its atoms with
EGFR to overcome the resistance problem.
In this work, we study the EGFR mutation-induced
drug resistance by analyzing structural properties of the
mutants in a dynamic form, based on the motion trajec-
tories obtained from molecular dynamics (MD) simulation.
The clinical data of EGFR mutation type and the drug
response of patients were collected from Queen Mary
Hospital in Hong Kong. We employed Rosetta to
model the EGFR mutants based on the crystal struc-
ture of wild-type (WT) EGFR and the mutant se-
quences [36]. Then Amber [37] was used to conduct
MD simulation to show the dynamic evolution of the
EGFR mutant-drug system. We extracted the trajectory
frames of each mutant and computed the alpha shape
model [38, 39] of each frame, in order to describe the
mutant with geometric models. Solid angle [33, 40]
was evaluated to characterize the curvature properties
of the atoms at the drug binding site. Finally, we com-
puted the knob level of the drug binding pocket of
each mutant and analyzed its relationship with the
drug response level. Results show that 90 % of the mu-
tants can be grouped correctly by setting a certain
knob level threshold.
Methods
Clinical data and ethics statement
The clinical data of NSCLC patients were collected from
Queen Mary Hospital in Hong Kong. This study was ap-
proved by Institutional Review Board of the University
of Hong Kong/Hospital Authority Hong Kong West
Cluster. Specifically, there are 137 patients belonging to
30 EGFR mutation types. The mutation type of each pa-
tient was obtained through an EGFR mutation test, in
which the mutations of the EGFR gene were detected by
analyzing the DNA of the tumor sample. All the patients
in our dataset took the tyrosine kinase inhibitor gefitinib
in the treatments. The potency of the drug was mea-
sured by drug response level (RL), which was obtained
by evaluating the selected target lesions of the patients,
based on measurement methods such as computed tom-
ography (CT) scan, magnetic resonance imaging (MRI)
and chest X-ray. According to the changes of the target
lesions, the RL can be categorized into four levels, complete
response (RL = 1), partial response (RL = 2), stable disease
(RL = 3) and progressive disease (RL = 4). Complete response
indicates that all the target lesions have disappeared. Partial
response means that at least a 30 % decrease of the target
lesions is measured compared with the sum of the longest
diameters (LDs) of the target lesions before treatment.
Stable disease and progressive disease take the smallest sum
of the LDs as reference. Stable disease donates that no suffi-
cient decrease or increase is noted, while at least a 20 % in-
crease is measured in progressive disease. For simplicity, we
can combine the complete response and partial response to
a drug Response group, while the other two are categorized
into a No-response group. Table 1 shows the RL of each
mutant, derived by the median RL value of the patients
Table 1 Drug response of the mutants
Mutant RL Mutant RL
delE746_T751insV 1 R776HL858R 2
delE746_T751insVA 1 delE746_T751insA 3
delE746_A750 2 delL747_A750insP 3
delE746_A750insAP 2 dulS768_D770 3
delE746_S752insV 2 G719CS768I 3
delE746_T751insI 2 R831H 3
delL747_A755insSKG 2 S768IV774M 3
delL747_P753insS 2 delE709_T710insD 4
delL747_T751 2 delL747_K754insANKG 4
delT751_I759insN 2 dulH773 4
E709KL858R 2 dulN771_H773 4
G719AL858R 2 E709AG719A 4
G719AL861Q 2 G724SL861Q 4
L858R 2 K757R 4
L861Q 2 L861R 4
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harboring this EGFR mutation type. These EGFR mutations
as well as their corresponding RLs were used for further
analysis in our study.
Modeling of EGFR mutants
Only several EGFR mutant crystal structures are available
from the Protein Data Bank (PDB) [41], due to the cost
and complexity in structure determination by experi-
ments. We adopted the released mutant structures
from PDB, such as L858R (PDB: 2ITZ), while modeled
most of them using Rosetta [36]. We carried out Rosetta
high-resolution ddg_monomer (HRDM) protocol and
comparative modeling (CM) protocol to generate the
EGFR mutants based on the crystal structure of WT
EGFR (PDB: 2ITY) [42, 43]. Rosetta ddg_monomer was
applied to predict the point mutation, such as L861Q
and G719C_S768I. Other mutation types such as
delE746_A750 (deletion), dulN771_H773 (duplication)
and delE746_A750insAP (modification) were modeled
by using the CM protocol. We further refined the pre-
dicted mutant structures using Amber [37], where 1000
steps of minimization were conducted to optimize the
structures. Figures 1a and b show the comparison of
the WT EGFR and the mutant delE746_A750insAP
modeled using Rosetta.
Molecular dynamics (MD) simulation
MD simulation can be used to study the interaction of
molecules for a fixed period of time, and record the
movements as trajectories which are determined by
solving Newton’s equations of motion. We employed
Amber 12 [37] to conduct MD simulation to the EGFR
mutant-drug complex. The complex was obtained by
aligning the predicted mutant structure to the WT
EGFR and appending drug molecule to it. Amber ff99SB
force field is adopted to describe the forces between parti-
cles in the simulation. As the simulation was performed in
a solvent environment, we solvated the complex into a
periodic TIP3P water box, where molecules exit one side
of the box will wrap to the other side. Then we conducted
a series of steps (minimization, heating, density equilibra-
tion, and constant pressure equilibration) to equilibrate
the system. At the environment of desired temperature,
density and pressure, the production MD simulation was
performed for 2 ns. We saved the motion trajectories
every 10 ps and a total of 200 trajectory frames were col-
lected for each mutant-drug complex.
Alpha shape modeling and solid angle calculation
After the motion trajectories of each mutant were obtained,
we carried out alpha shape modeling for each trajectory
frame, in order to show the surface geometric properties of
the mutant structure. The alpha shape [38, 39] can provide
effective approximation of the original shape of a molecule
with a computational geometric model. We employed
Computational Geometry Algorithms Library (CGAL) [44]
to generate the weighted alpha shape models of the EGFR
mutants. Figures 1c and d show the alpha shape models of
the drug binding pocket of WT EGFR and the mutant
delE746_A750insAP, respectively.
Fig. 1 a and b show the comparison of the crystal structures of WT EGFR and the mutant delE746_A750insAP. c and d are the alpha shape
models of the drug binding pocket of (a) and (b), respectively. The original site is colored blue while the corresponding mutant site is shown in
magenta. The drug molecule (gefitinib) is displayed in purple
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Fig. 2 a and b show the solid angle values at the drug binding site of the first trajectory frame of the mutants delE709_T710insD and
delL747_T751, respectively. The dark dashed lines indicate the position of 0. c and d demonstrate the number of convex and concave atoms
with different solid angle value thresholds at the drug binding site of the two mutants
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Fig. 3 The comparison of average convex degrees of the drug Response mutants delE746_T751insVA (RL = 1, shown in a, c and e) and
delL747_P753insS (RL = 2, shown in b, d and f), and the No-response ones L861R (RL = 4), dulN771_H773 (RL = 4) and G724S_L861Q (RL = 4). The
drug Response mutants are shown in blue, while the No-response ones are colored red
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Then we used solid angle to characterize the geometric
properties of each atom at the drug binding site. Solid
angle describes the curvature by providing a value (in the
range of [−1, 1]) to show the concave or convex properties
of each surface atom. If the solid angle value falls in [−1,
0), the shape is defined as a concave one while a convex
shape is obtained if the value is in (0, 1]. The detailed def-
inition of solid angle can be found in [33, 40].
Results and Discussion
Based on the motion trajectories obtained from MD
simulation, we carried out alpha shape modeling for all
the 30 EGFR mutants. A total of 200 trajectory frames
were collected in the production MD simulation process.
Thus, the alpha shape model was built for 200 times for
each mutant. Then we used solid angle to characterize
the atoms at the drug binding site. In this study, the drug
binding site of a mutant structure was defined as the
amino acid residues at the drug binding site of the WT
EGFR. Specifically, a total of 14 residues of 102 atoms are
involved at the drug binding site of the WT EGFR. A few
mutations locate just at the drug binding site, such as
G719A_L858R, while the majority of mutations do not.
We computed the solid angles of all the atoms at the
drug binding site, and the values of those who were not
at the surface of the drug binding site were set to zero.
Figures 2a and b show the solid angle values at the first
trajectory frame of the mutants delL747_T751 (RL = 2)
and delE709_T710insD (RL = 4). According to the RLs of
the two mutants, they are classified to the drug Response
Fig. 4 The relationship of knob level and drug response level of the 30 mutants, with the solid angle value threshold setting to 0, 0.01 and 0.02,
respectively. a to c show the scatter plots of the mutants for each drug response level. d to f are the corresponding box plots of (a) to (c)
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and No-response group, respectively. As shown in the
two figures, the number of convex atoms of the mutant
delE709_T710insD is more than that of delL747_T751.
Then we counted the number of convex and concave
atoms for all the 200 trajectory frames of the two
mutants respectively, and even made a further step to
calculate the number of atoms with SA (solid angle
value) > 0.5 or SA < − 0.5. Figures 2c and d indicate
that the concave indexes of the two mutants are mixed
together while the convex ones are clearly separated.
Consequently, we only consider the convex-related char-
acteristics of the mutants in the following studies.
First, we computed the average convex degree of the
drug binding site for all the motion trajectory frames of
each mutant. For a specific trajectory frame, the average
convex degree was calculated as the sum of all the solid
angle values of convex atoms at the drug binding site di-
vided by the total number of convex atoms in this area.
Figure 3 shows the comparison of average convex degree
of the drug Response mutants delE746_T751insVA (RL = 1)
and delL747_P753insS (RL = 2), and the No-response
ones L861R (RL = 4), dulN771_H773 (RL = 4) and
G724S_L861Q (RL = 4). Although the two groups of mu-
tants cannot be separated perfectly, the average convex
degree of delE746_T751insVA and delL747_P753insS are
generally lower than that of L861R, dulN771_H773 and
G724S_L861Q.
Then we defined knob level, the mean of the average
convex degrees for the 200 trajectory frames, to
characterize the drug binding site of each mutant. The
solid angle values of some atoms are very close to zero
(Figs. 2a and b), making a large difference on the average
convex degree of each trajectory frame. Therefore, we
set a solid angle value threshold to avoid their influence.
Afterwards, we explored the relationship between knob
level and drug response level of the 30 mutants. The re-
sults are shown in Fig. 4, with solid angle value thresh-
old setting to 0, 0.01 and 0.02 respectively. Figures 4a
to c are the scatter plots of the mutants. When the
threshold equals to 0.01, the mutants of the Response
and No-response groups can be separated with only 3
errors (3 mutants belonging to RL = 2 are wrongly cate-
gorized). Figures 4d to f shows the corresponding box
plots of Figs. 4a to c, respectively. As shown in these
figures, the median knob level values (bands inside the
boxes) of the four drug response level groups are clearly
separated. In addition, the main bodies (boxes) of the
two groups (Response and No-response) of mutants are
a                                                         b
c                                                         d
e                                                         f

















































Fig. 5 a to d presents the comparison of the solid angle values of the atoms at the average binding site of the drug Response mutants
delE746_T751insV (RL = 1, a and c) and delE746_A750 (RL = 2, b and d), and the No-response ones delL747_K754insANKG (RL = 4) and
S768I_V774M (RL = 3). The drug Response and No-response mutants are shown in blue and red, respectively. e and f show the statistics of the
convex atoms and the atoms with SA > 0.7 at the average binding site of the 30 mutants. The mutants of each response level group are sorted
in an ascending order by the number of convex atoms. Blue, red, green and magenta correspond to mutants with RL = 1, 2, 3 and 4
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at different knob levels, when the threshold equals to
0.01 or 0.02.
Besides the aforementioned definition of knob level,
we alternatively computed the mean of the solid angle
value of each atom at the drug binding site from the 200
trajectory frames. In this way, an average drug binding
site of each mutant was obtained. Thus, we used the
average convex degree of this drug binding site as the
knob level to describe the mutant. Figures 5a to d show
the comparison of the solid angle values of the atoms at
the average binding site of the drug Response mutants
delE746_T751insV (RL = 1) and delE746_A750 (RL = 2),
and the No-response ones delL747_K754insANKG (RL =
4) and S768I_V774M (RL = 3). Although there is not
much difference between the total number of convex
atoms of the Response and No-response groups, the solid
angle values of convex atoms in the No-response group
are generally greater than that of the Response group.
We also counted the number of convex atoms (SA > 0)
and the number of atoms with SA > 0.7 at the average
drug binding site of each mutant (Figs. 5e and f). The
number of convex atoms of the 30 mutants is irregular
for different response level groups. However, the number
of atoms with SA > 0.7 of the No-response group is equal
to or more than that of the Response group.
Afterwards, we used the average convex degree (the
sum of all the solid angle values of convex atoms at the
average drug binding site divided by the total number of
convex atoms in this area) to characterize the knob level
of the average drug binding site of each mutant. Similarly,
Fig. 6 The relationship between the knob level of the average binding site and the drug response level of the mutants, with the solid angle
value threshold setting to 0, 0.01 and 0.02 respectively
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some solid angle values are close to zero, and we set a
solid angle value threshold to remove their influence. The
relationship between knob level and drug response level
of the mutants are shown in Fig. 6. When the solid angle
value threshold equals to 0.01 or 0.02, only three mutants
of the two groups (Response and No-response groups) are
wrongly distinguished by setting a certain knob level
boundary (dark dashed lines in Figs. 6b and c), showing
an accuracy of 90 % (27/30). In addition, the main bodies
of the two groups of mutants are in different knob level
ranges.
Conclusions
In this study, we analyzed the motion trajectories of the
EGFR mutants obtained from MD simulation. The EGFR
mutant structures were generated using Rosetta. Amber
was employed to carry out MD simulation of the EGFR
mutant-drug system. The motion trajectories were col-
lected every 10 ps and a total of 200 frames were obtained
for each mutant. Then we computed alpha shape model
of each trajectory frame and characterized the curvature
of the atoms at the drug binding site using the solid angle.
In one aspect, we calculated the average convex degree at
the drug binding site of each trajectory frame, and ob-
tained the knob level of a mutant by computing the mean
value of the convex degrees of the 200 frames. On the
other hand, we calculated the mean of the solid angle
value of each atom at the drug binding site from the 200
trajectory frames. In this way, an average drug binding site
could be obtained, and the average convex degree of this
binding site was calculated to measure the knob level of a
mutant. Finally, we analyzed the relationship between the
knob level of the drug binding site and the drug response
level of the mutants. Results show that 90 % of the mu-
tants can be grouped correctly by setting a certain knob
level threshold.
To validate our model, we can compare the predicted
response with the clinically obtained drug response of
the EGFR mutants collected from literature. Meanwhile,
the newly collected clinical data provide resources to
refine our model to make further prediction more ac-
curately. For example, L858R_T790M is a well-known
mutant which is resistant to gefitinib. Then we can
compute its alpha shape model and derive the knob
level of the drug binding pocket in the aforementioned
two ways. As the best grouping accuracy is achieved
when the solid angle threshold equals to 0.01 for both
the two way situations (Figs. 4b and b). We set the
threshold to 0.01, and obtained the knob level of
0.5298 and 0.4964 with the two approaches, respect-
ively. According to knob level thresholds of the drug
Response mutants and the No-response ones in Figs. 4b
and b, the mutant of L858R_T790M can be categorized
to the No-response group, which is consistent with our
knowledge.
By using the obtained relationships between knob level
and drug response level of the EGFR mutants, we can
have a general classification of a new EGFR mutant before
measuring the drug response from clinical evaluation. We
can model the 3D structure as well as the alpha shape of a
new EGFR mutant to derive the knob level of the drug
binding pocket. According to the obtained knob level
threshold of the drug Response and No-response groups,
we are able to predict the drug response of the new
mutant. The results can be used for clinical guidance and
can benefit the patients with a more effective therapy.
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